An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing's syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Dec 2018 Planned End Date changed from 27 Sep 2023 to 24 Oct 2023.
- 04 Oct 2018 Planned End Date changed from 18 Jul 2023 to 27 Sep 2023.
- 04 Oct 2018 Status changed from not yet recruiting to recruiting.